The recent emergence of Coronavirus Disease in 2019 (COVID-19), caused by infection by SARS-CoV-2, has put the world on high alert. People are concerned about how soon drugs and vaccines will be available after the isolation of virus strains and the completion of sequencing and comparative analysis.
Read More ›
2월 25일에, Cyagen Biosciences Suzhou Inc.는 2억8500만 위안 (약 4,400 만 달러 상당)의 시리즈 B 파이낸싱을 완성했으며 이 투자는 GF증권(GF securities)가 전액 소유하고 있는 CMS Capital, GF Qianhe, GF Xinde 및 광화투자(Guanghua Investment)가 관리하는 펀드입니다.
Read More ›
At the end of 2019, an outbreak of the COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, swept across the world from Wuhan - having brought a huge impact on the lives of the people in China.
Read More ›
Are you considering custom animal models to accelerate your next research project? Cyagen's Discount of the Decade Event can help you extend your research with big savings for multiple projects - the more animal models you order from any eligible service, the more you save!
Read More ›
Since the identification of the intermediate filament (IF), nestin, it has been used as a marker for Neural Stem Cells (NSCs) and commonly considered as a key component of the cytoskeleton.
Read More ›
Since the early 2000s, large-scale knockout consortia have been established with the goal of generating a complete resource of reporter-tagged null mutations in C57BL/6 mouse ES cells. Herein, we provide a brief introduction to the ‘knockout-first’
Read More ›
As CRISPR-based innovations begin to move into clinical testing and the dispute over core patents continues worldwide, CRISPR-Pro gene editing has been under increased scrutiny in both commercial and academic sectors.
Read More ›
Synaptic impairment is known to be a prerequisite to the cognitive deficiencies exhibited in Alzheimer's Disease (AD), so investigating the mechanisms which
Read More ›
We use cookies to ensure that we give you the best experience on our website. To learn about how we
keep your information safe, view our Privacy Policy.
OKPrivacy policy